Depomed Development

Assertio, formerly known as Depomed, is a commercial-stage specialty pharmaceutical company focused on neurology, pain management, and inflammation. The company is recognized for its proprietary Acuform drug delivery technology, which utilizes a gastric-retentive polymer matrix to provide controlled release of small molecule therapeutics. In 2018, the company rebranded from Depomed to Assertio Therapeutics to signal a strategic shift toward a more diversified asset portfolio and a leaner operating model. Its current commercial lineup includes well-established brands such as Gralise for postherpetic neuralgia and Indocin for various inflammatory conditions. Headquartered in Lake Forest, Illinois, Assertio continues to execute a strategy centered on the acquisition and optimization of branded pharmaceutical products.